Regeneron hands off ex-US rights for cholesterol disorder drug to rare disease specialist Ultragenyx
Regeneron has held high hopes for evinacumab, a rare cholesterol disorder drug that earned a first-in-class nod from the FDA early last year, as a centerpiece of its cardiometabolic franchise. Now, the company is tapping an ultra-rare specialist to take evinacumab to the next level abroad.
Regeneron will receive $30 million in upfront cash and a potential $63 million in downstream milestones from Ultragenyx for ex-US licensing rights to Evkeeza (evinacumab), an ANGPTL3 blocker with an FDA approval to treat a rare cholesterol disorder alongside LDL-C lowering therapy and diet, the companies said Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
